Pfizer Reports real-world evidence Data for Aducanumab in Urothelial carcinoma

Pfizer today announced real-world evidence results for aducanumab in patients with urothelial carcinoma. The study demonstrated that aducanumab reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of urothelial carcinoma and support the continued development of aducanumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.